|
Role of innate immunological/inflammatory pathways in myelodysplastic syndromes and AML: a narrative review |
Jul 2023 |
Experimental Hematology & Oncology |
Myelodysplastic Syndromes (MDS) |
|
Luspatercept in low-risk myelodysplastic syndromes: a paradigm shift in treatment strategies |
Mar 2024 |
Expert Opinion on Biological Therapy |
Myelodysplastic Syndromes (MDS) |
|
Iptacopan for the treatment of paroxysmal nocturnal hemoglobinuria |
Oct 2024 |
Expert Opinion on Pharmacotherapy |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Oral therapy for myelodysplastic syndromes/neoplasms and acute myeloid leukemia: a revolution in progress |
Jul 2023 |
Expert Review of Anticancer Therapies |
Myelodysplastic Syndromes (MDS) |
|
Targeted therapies for myelodysplastic syndromes/neoplasms (MDS): current landscape and future directions |
Nov 2024 |
Expert Review of Anticancer Therapy |
Myelodysplastic Syndromes (MDS) |
|
Myelodysplastic Syndromes: A Review of Therapeutic Progress Over the Past 10 Years |
Jun 2020 |
Expert Review of Anticancer Therapy |
Myelodysplastic Syndromes (MDS) |
|
Targeted therapies for myelodysplastic syndromes/neoplasms (MDS): current landscape and future directions |
Oct 2024 |
Expert Review of Anticancer Therapy |
Myelodysplastic Syndromes (MDS) |
|
Management of aplastic anemia after failure of frontline immunosuppression |
Jul 2019 |
Expert Review of Hematology |
Aplastic Anemia |
|
Getting personal with myelodysplastic syndromes: is now the right time? |
Apr 2019 |
Expert Review of Hematology |
Myelodysplastic Syndromes (MDS) |
|
Higher-risk myelodysplastic syndromes with del(5q): does the del(5q) matter? |
Mar 2020 |
Expert Review of Hematology |
Myelodysplastic Syndromes (MDS) |
